MILLIPLEX^® Human Th17 Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 25 analytes in human serum, plasma, and cell culture supernatants.Analytes included: GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IL-17F, IL-17E/IL-25, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, MIP-3α/CCL20, TNF-α, TNFβAssay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Multiplex Capability: Enables simultaneous quantification of multiple Th17-related cytokines in a single assay, maximizing data output from minimal sample volume.Compact Design: The space saver format reduces storage requirements while maintaining the same high-quality performance as standard panels.Supports Autoimmune Disease Research: Enables profiling of Th17 cytokines implicated in diseases like multiple sclerosis, rheumatoid arthritis, Crohn′s disease, psoriasis, and juvenile diabetes.Ideal for Tumor Immunology Studies: Investigates Th17 cells′ dual role in tumor progression and inhibition, helping researchers understand immune modulation in cancer.

CD4 T-helper cells are major players in adaptive immunity. Based on their expression profile of transcription factors and secreted cytokines, these cells are divided into the major subsets Th1, Th2, Th17 and T regulatory (Treg) cells. Th1 cells, induced by IL-12 and enhanced by IFNγ, secrete IFNγ that activates macrophages. Induced by IL-4, Th2 cells primarily produce IL-4, IL-5, IL-13, IL-25 and IL-17E, playing a role in allergy. Treg cells, induced by TGFβ, produce the anti-inflammatory cytokines IL-10 and TGFβ and function to control T-cell responses to prevent autoimmune reactions. Th17 cells, a more recently discovered subset characterized by the production of IL-17, are induced by TGFβ combined with IL-23 and IL-1β in humans, and TGFβ, IL-6 and IL-21 in mice. Activated Th17 cells secrete IL-17A, IL-17F, IL-21, IL-22 and TNFα to promote tissue inflammation. Th17 cells are involved in the clearance of extracellular bacteria and fungi. They are abundant in the intestinal lamina propria and function as a barrier against invading pathogens. Excessive amounts of Th17 cells have been implicated in the pathogenesis of several autoimmune diseases, including multiple sclerosis, psoriasis, juvenile diabetes, rheumatoid arthritis, Crohn′s disease, and autoimmune uveitis. In addition, Th17 cells play an important role in tumor development, progression, and metastasis, potentially in both promoting and inhibiting tumor growth.